Future Oncology · 2019 · 33 citations · 26 references
MedicineImmunologyOncologyCancer ImmunologyInflammationTumor ImmunologyCancer BiomarkersCancer Survival AnalysisImmuno-oncology BiomarkersInflammatory BiomarkersNeutrophil BiologyCox RegressionKaplan-meier Confidence IntervalsNeutrophil-to-lymphocyte RatioPretreatmentPrognostic BiomarkersPrognostic IndicesPrognostic ModelsSystemic Inflammation Markers
Aim: The purpose of this study was to investigate the predictive power of the systemic immune inflammation index (SII) based on neutrophil (N), platelet (P) and lymphocyte (L) on the clinical outcomes of patients with SCLC. Patients & methods: Blood samples of 228 patients were obtained 1 week before treatment to measure the SII (SII = P × N/L). Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier curves and Cox regression models. Results: Higher SII was associated with poorer OS (p < 0.001) and poorer PFS (p < 0.001). Multivariable analyses further revealed SII as an independent prognostic factor for OS (p < 0.001) and PFS (p < 0.001). Conclusion: Pretreatment SII was a valuable prognostic factor for PFS and OS in SCLC patients.
26
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Systemic immune-inflammation index for predicting prognosis of colorectal cancer
Jianhui Chen, Ertao Zhai, Yujie Yuan et al. · World Journal of Gastroenterology · 2017 · 740 citations · Full text
Medicine, Immunology, Oncology +16